TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33908377
Drug: Treatment disclosure
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment disclosure
Study: 33908377
Drug: Tolerance for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolerance for stimulant misuse and diversion
Study: 33908377
Drug: Peer norms
Normalized name: Worm Protector 2X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer norms favorable to stimulant misuse and diversion
Study: 35933897
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg shilajit extract
Study: 35933897
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg shilajit extract
Study: 38236575
Drug: Olaparib 300
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg twice daily
Study: 34984539
Drug: GEN0101 (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEN0101 (low dose: 30,000 mNAU)
Study: 34984539
Drug: GEN0101 (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEN0101 (high dose: 60,000 mNAU)
Study: 35176134
Drug: Mini-dose glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mini-dose glucagon (MDG)
Study: 35176134
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tablets (OG)
Study: 34077032
Drug: Lemborexant 5
Normalized name: lemborexant 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant 5 mg
Study: 39266012
Drug: Lemborexant 10
Normalized name: lemborexant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant 10 mg
Study: 32468649
Drug: Lemborexant 10
Normalized name: lemborexant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant 10 mg/day
Study: 32468649
Drug: Lemborexant (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant (doses through 25 mg)
Study: 34888654
Drug: Pulse dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pulse dexamethasone (3 mg/kg/day, max 100 mg/day)
Study: 32145129
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid 5-10 mg
Study: 36813656
Drug: Bempedoic acid
Normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bempedoic acid 180 mg once daily
Study: 35334548
Drug: Specialized physical
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized physical therapy with partial body weight supported treadmill training
Study: 35334548
Drug: Specialized physical
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized physical therapy without partial body weight supported treadmill training
Study: 32361773
Drug: Curcuma longa
Normalized name: Curcuma Longa
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuma longa L. extract (CLE) 3 capsules per day, 500 mg each
Study: 32361773
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) 3 capsules per day, 500 mg of microcrystalline cellulose
Study: 38926142
Drug: treatment-as-usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment-as-usual (TAU)
Study: 32275031
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of papaverine with left stellate ganglion blockade (LSGB)
Study: 32275031
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of papaverine alone (Control Group-C)
Study: 34391687
Drug: Intravenous nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicorandil application plus routine care
Study: 34391687
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional diuretics, positive inotropic agents, and related therapy according to the guidelines)
Study: 32331019
Drug: HP-3070 high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP-3070 high-dose
Study: 32331019
Drug: HP-3070 low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HP-3070 low-dose
Study: 35272029
Drug: Corticosteroids +
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids + mesalamine (4 g/day)
Study: 36094813
Drug: Standard 8-session
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 8-session web-based mindfulness-based cognitive therapy (MBCT)
Study: 32113994
Drug: Steroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid therapy (dexamethasone 4 mg three times daily for 5 days)
Study: 34205551
Drug: Daily physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physical activity text message reminders (Intervention Group)
Study: 33565825
Drug: Local administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local administration of 80 mg of triamcinolone
Study: 32843079
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron isomaltoside (1000 mg)
Study: 32843079
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation (100 mg ferrous fumarate with 60 mg ascorbic acid)
Study: 34714120
Drug: SDX/d-MPH (39.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDX/d-MPH (39.2 mg/7.8 mg/day, titrated to maximum dose of 52.3/10.4 mg)
Study: 35135624
Drug: Non-prescription pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-prescription pad
Study: 35613727
Drug: MVA at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA at weeks 0/8 + LIPO‐5 at weeks 20/28 (M/L)
Study: 35613727
Drug: LIPO‐5 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIPO‐5 at weeks 0/8 + MVA at weeks 20/28 (L/M)
Study: 35613727
Drug: DNA at
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA at weeks 0/4/12 + LIPO‐5 at weeks 20/28 (G/L)
Study: 35613727
Drug: DNA at
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA at weeks 0/4/12 + MVA at weeks 20/28 (G/M)
Study: 35613727
Drug: MVA-receiving groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-receiving groups (M/L, L/M, G/M)
Study: 35613727
Drug: MVA-receiving groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-receiving groups (M/L, G/M)
Study: 35802649
Drug: Targeted therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapies (TT) including selumetinib, vistusertib, capivasertib, AZD4547, AZD8931, vandetanib, olaparib, savolitinib
Study: 32628509
Drug: Phonomotor Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonomotor Therapy (PMT)
Study: 33568628
Drug: UC-MSCs (4×10^7
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC-MSCs (4×10^7 cells per infusion)
Study: 39028879
Drug: Triple antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antithrombotic therapy (TAT)
Study: 35105533
Drug: Double antithrombotic
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double antithrombotic therapy (DAT)
Study: 32311976
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with Jianpi Yangzheng Xiaozheng decoction (JPYZXZ)
Study: 32979907
Drug: Topical atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical atorvastatin 5% cream plus topical betamethasone 1% ointment
Study: 32979907
Drug: Topical betamethasone
Normalized name: betamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betamethasone 1% ointment plus vehicle cream
Study: 34971258
Drug: Cognitive stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive stimulation virtual therapy (CSVT) program, 6 months, 2 sessions per week (N = 10)
Study: 34971258
Drug: Cognitive stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive stimulation virtual therapy (CSVT) program
Study: 35687761
Drug: lacutamab (anti-KIR3DL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: lacutamab (anti-KIR3DL2 humanized antibody)
Study: 32432798
Drug: Tildrakizumab (IL-23p19
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tildrakizumab (IL-23p19 inhibitor)
Study: 34427473
Drug: Recombinant factor
Normalized name: Recombinant factor IX
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant factor VIIa (rFVIIa) 80 µg/kg intravenously over 2 min
Study: 32610647
Drug: Arginine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine (2 × 6 g/day) with IHE
Study: 32586363
Drug: Hydroxychloroquine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (200 mg tablet every other day for 2 months)
Study: 32586363
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical in terms of shape, colour, smell, 200 mg tablet every other day for 2 months)
Study: 89155066
Drug: Chlordiazepoxide and
Normalized name: Chlordiazepoxide and clidinium only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordiazepoxide and chlorpromazine combination
Study: 32815386
Drug: Electroacupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture plus warm needling (EAWN) therapy
Study: 36159932
Drug: Waitlist control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist control (no treatment)
Study: 33175132
Drug: High-dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD) IIV followed by standard dose (SD) vaccine (HD-SD arm)
Study: 33175132
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (SD) vaccines (SD-SD arm)
Study: 33012264
Drug: Difficulty paying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difficulty paying monthly bills mediation
Study: 32649760
Drug: Bolus 30-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus 30-g dose of LNS
Study: 32649760
Drug: Divided 3
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided 3 × 10-g doses of LNS
Study: 36112256
Drug: LipiFlow® thermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: LipiFlow® thermal pulsation treatment
Study: 33233658
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (IF with 0.8 g/100 mL scGOS/lcFOS (9:1))
Study: 34987350
Drug: Psychosocial occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial occupational therapy combined with anodal tDCS (12 sessions, 20 minutes, 2 mA intensity on the left DLPFC)
Study: 35339987
Drug: L-arginine (1.66
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (1.66 g, twice a day for 3 weeks)
Study: 35339987
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical aspect, no L-arginine, twice a day for 3 weeks)
Study: 32641240
Drug: ADXS-HPV (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADXS-HPV (1 × 10^9 colony-forming units in 250 mL IV over 15 min every 28 days)
Study: 34106758
Drug: IV thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV thrombolytic treatment
Study: 34871782
Drug: Smartphone-based daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-based daily feedback and counseling platform (App group)
Study: 33908425
Drug: Continuous femoral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous femoral nerve block (NB) with ropivacaine through an NB catheter and a sham saline periarticular injection (PI).
Study: 33908425
Drug: Periarticular injection
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injection (PI) of ropivacaine, morphine, ketorolac, and epinephrine, with a sham saline infusion via an NB catheter.
Study: 35000455
Drug: Drug-Coated Balloons
Normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug-Coated Balloons (DCB)
Study: 35657971
Drug: Environmental control
Normalized name: ZINC OXIDE 225 mg in 100 mL TOPICAL CREAM [ENVIRONMENTAL DEFENSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Environmental control strategies (ECS) plus asthma controller medication titration
Study: 35657971
Drug: Controller medication
Normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controller medication titration alone
Study: 33427618
Drug: Pegloticase (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegloticase (8 mg every 2 weeks or monthly)
Study: 33427618
Drug: Pegloticase (monthly)
Normalized name: Pegloticase
DrugBank: Pegloticase (DB09208)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegloticase (monthly)
Study: 32065831
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 10 μg of IFN‐β‐1a once daily for 6 days
Study: 32065831
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 10 μg of IFN‐β‐1a
Study: 36180115
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) with a prescription dose of 30‐50 Gy in 3‐5 fractions
Study: 32100275
Drug: Combined-ABT (linzagolix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-ABT (linzagolix 200 mg/ABT for 10 weeks)
Study: 32100275
Drug: Delayed-ABT (linzagolix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-ABT (linzagolix 200 mg for 4 weeks followed by linzagolix 200 mg/ABT for 6 weeks)
Study: 37022706
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg IV every 2 weeks)
Study: 39167807
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg orally once daily)
Study: 35616653
Drug: Habit formation
Normalized name: formate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Habit formation treatment delivered face to face during 12 weekly home‐based sessions (45 min each)
Study: 35616653
Drug: Habit formation
Normalized name: formate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Habit formation (mechanism of change) assessed in treatment group only
Study: 35714174
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg iv morphine
Study: 36209091
Drug: Crocin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocin (15 mg/day) for 90 days
Study: 32443963
Drug: Traditional multicomponent
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional multicomponent training (MG)
Study: 32032566
Drug: PRIMVAC adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRIMVAC adjuvanted with GLA-SE (100 μg dose)
Study: 32032566
Drug: PRIMVAC adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRIMVAC adjuvanted with Alhydrogel (100 μg dose)
Study: 32032566
Drug: PRIMVAC (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRIMVAC (100 μg dose and GLA-SE)
Study: 32032566
Drug: PRIMVAC (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRIMVAC (100 μg dose)
Study: 32141373
Drug: In-home iPad
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-home iPad lessons (8 weekly sessions)
Study: 34527611
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intravenous zoledronic acid
Study: 34527611
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intravenous zoledronic acid
Study: 34527611
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg and 4 mg intravenous zoledronic acid
Study: 34919247
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 400 mg twice a day
Study: 34919247
Drug: Ursodeoxycholic Acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic Acid 250 mg twice a day
Study: 34919247
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg twice a day
Study: 33838673
Drug: Chlorogenic acid
Normalized name: chlorogenic acid
DrugBank: Chlorogenic Acid (DB12029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorogenic acid plus caffeine 200 mg each
Study: 32110819
Drug: Al/Mg hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Al/Mg hydroxide antacid
Study: 32110819
Drug: Control Group-1
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group-1 (no antacid)
Study: 34001667
Drug: PRN 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRN 0.5 mg conbercept intravitreal injections
Study: 34001667
Drug: Laser photocoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser photocoagulation followed by PRN sham intravitreal injections
Study: 36364735
Drug: Specific collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific collagen peptide preparation (test group; n = 20)
Study: 33105594
Drug: Diode Laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode Laser Therapy
Study: 33105594
Drug: CO2 Laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 Laser Therapy
Study: 34348704
Drug: Knee sleeve
Normalized name: Knee Sleeve Large
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knee sleeve worn for 6 weeks, at least 1 hour daily.
Study: 34625826
Drug: Non-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment control (CON)
Study: 34242497
Drug: Silymarin (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (140 mg silymarin capsules thrice daily)
Study: 36438970
Drug: Active treatments
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatments
Study: 34487062
Drug: cONS (energy-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: cONS (energy-dense pediatric oral nutritional supplements)
Study: 34487062
Drug: sONS (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: sONS (standard oral nutritional supplements)
Study: 32648396
Drug: Electro-nape-acupuncture combined
Normalized name: combinations of electrolytes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-nape-acupuncture combined with hyperbaric oxygen therapy (ENA+HBOT)
Study: 33006057
Drug: N-Pep-12 dietary
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-Pep-12 dietary supplementation (90 mg daily for 90 days)
Study: 33135666
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 3D virtual reality and horticultural therapy (9-week intervention)
Study: 34535047
Drug: Carbetocin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin (100 mcg)
Study: 32552430
Drug: Isometric training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isometric training of the tibialis anterior (TA) at long muscle-tendon unit length (L-group)
Study: 32552430
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (S-group and L-group)
Study: 36352479
Drug: Semi-structured interviews
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-structured interviews with trial participants, employers, therapists, and therapy service managers.
Study: 35063228
Drug: 1.8 g
Normalized name: Calciquid, 1.8 g/5 mL oral syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g of protein/amino acids per kg body weight per day
Study: 35063228
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g of protein/amino acids per kg body weight per day
Study: 34236130
Drug: Higher pre-HD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher pre-HD serum phosphate (per 1 mg/dl)
Study: 34518310
Drug: BAY 1217389
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1217389 (64 mg twice daily) with weekly paclitaxel (90 mg/m2)
Study: 34518310
Drug: Paclitaxel monotherapy
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel monotherapy
Study: 33285389
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Omega-3 and IF-PEP
Study: 34286472
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D (cholecalciferol 100,000 UI per 10 days over 1 month)
Study: 34286472
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin D (ergocalciferol 400 UI/days over 1 month)
Study: 33677928
Drug: Romosozumab (210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romosozumab (210 mg, monthly subcutaneous injections)
Study: 35460726
Drug: Vebicorvir (VBR)
Normalized name: Vebicorvir
DrugBank: Vebicorvir (DB18784)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vebicorvir (VBR) 300 mg once daily + NrtIs
Study: 35287509
Drug: Cows’ milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cows’ milk 20% topical ointment applied once daily for two weeks.
Study: 35287509
Drug: Novel dressing
Normalized name: DRESSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel dressing used for control group, applied once daily for two weeks.
Study: 35287509
Drug: Cows’ milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cows’ milk 20% topical ointment
Study: 34188053
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by definitive chemoradiotherapy (CRT)
Study: 34909518
Drug: Eplerenone 50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 50 mg daily
Study: 33671166
Drug: Unripe banana
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unripe banana flour (UBF) 21 g/day
Study: 33671166
Drug: Placebo (waxy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (waxy corn starch 12 g/day)
Study: 32852460
Drug: Phytoestrogens (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytoestrogens (75 mg soy isoflavones, BID)